Influence of avicel PH-301 on the compressibility of α-methyldopa and phenobarbitone in direct compression

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The aim of this work was to investigate the compressibility behavior of α-methyldopa and phenobarbitone using a Korsch EKO instrumented eccentric tablet machine, with force-time and force-displacement curves constructed and applied to calculate different compressional values to study the compressional behavior. The results of this work revealed a difference in compressibility behavior between the two drugs during the compressional process, α-Methyldopa gave an abnormal compressional curve with high friction in the pre- and postcompressional phases. A residual force could be seen on the lower punch. Furthermore, capping and sticking were observed visually during tablet pressing, indicating poor compressibility behavior. In the case of phenobarbitone, no friction was observed in the precompressional phase, but there was higher friction in the postcompressional phase, especially in the ejection phase. The compressibility of the drugs was improved by the addition of Avicel PH-301 and magnesium stearate.

Original languageEnglish
Pages (from-to)1013-1018
Number of pages6
JournalDrug Development and Industrial Pharmacy
Volume26
Issue number9
DOIs
Publication statusPublished - 2000

Fingerprint

Methyldopa
Friction
Phenobarbital
Compressibility
Cellulose
Compaction
Tablets
Pharmaceutical Preparations

Keywords

  • Compressibility
  • Compressibility behavior
  • Compressional curves
  • Direct compression
  • Plasticity

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology
  • Molecular Medicine

Cite this

@article{99fda4398e244484b4d9ece04af133b5,
title = "Influence of avicel PH-301 on the compressibility of α-methyldopa and phenobarbitone in direct compression",
abstract = "The aim of this work was to investigate the compressibility behavior of α-methyldopa and phenobarbitone using a Korsch EKO instrumented eccentric tablet machine, with force-time and force-displacement curves constructed and applied to calculate different compressional values to study the compressional behavior. The results of this work revealed a difference in compressibility behavior between the two drugs during the compressional process, α-Methyldopa gave an abnormal compressional curve with high friction in the pre- and postcompressional phases. A residual force could be seen on the lower punch. Furthermore, capping and sticking were observed visually during tablet pressing, indicating poor compressibility behavior. In the case of phenobarbitone, no friction was observed in the precompressional phase, but there was higher friction in the postcompressional phase, especially in the ejection phase. The compressibility of the drugs was improved by the addition of Avicel PH-301 and magnesium stearate.",
keywords = "Compressibility, Compressibility behavior, Compressional curves, Direct compression, Plasticity",
author = "M. Siaan and K. Pintye-H{\'o}di and P. Szab{\'o}-R{\'e}v{\'e}sz and P. K{\'a}sa and I. Er{\"o}s",
year = "2000",
doi = "10.1081/DDC-100101331",
language = "English",
volume = "26",
pages = "1013--1018",
journal = "Drug Development and Industrial Pharmacy",
issn = "0363-9045",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Influence of avicel PH-301 on the compressibility of α-methyldopa and phenobarbitone in direct compression

AU - Siaan, M.

AU - Pintye-Hódi, K.

AU - Szabó-Révész, P.

AU - Kása, P.

AU - Erös, I.

PY - 2000

Y1 - 2000

N2 - The aim of this work was to investigate the compressibility behavior of α-methyldopa and phenobarbitone using a Korsch EKO instrumented eccentric tablet machine, with force-time and force-displacement curves constructed and applied to calculate different compressional values to study the compressional behavior. The results of this work revealed a difference in compressibility behavior between the two drugs during the compressional process, α-Methyldopa gave an abnormal compressional curve with high friction in the pre- and postcompressional phases. A residual force could be seen on the lower punch. Furthermore, capping and sticking were observed visually during tablet pressing, indicating poor compressibility behavior. In the case of phenobarbitone, no friction was observed in the precompressional phase, but there was higher friction in the postcompressional phase, especially in the ejection phase. The compressibility of the drugs was improved by the addition of Avicel PH-301 and magnesium stearate.

AB - The aim of this work was to investigate the compressibility behavior of α-methyldopa and phenobarbitone using a Korsch EKO instrumented eccentric tablet machine, with force-time and force-displacement curves constructed and applied to calculate different compressional values to study the compressional behavior. The results of this work revealed a difference in compressibility behavior between the two drugs during the compressional process, α-Methyldopa gave an abnormal compressional curve with high friction in the pre- and postcompressional phases. A residual force could be seen on the lower punch. Furthermore, capping and sticking were observed visually during tablet pressing, indicating poor compressibility behavior. In the case of phenobarbitone, no friction was observed in the precompressional phase, but there was higher friction in the postcompressional phase, especially in the ejection phase. The compressibility of the drugs was improved by the addition of Avicel PH-301 and magnesium stearate.

KW - Compressibility

KW - Compressibility behavior

KW - Compressional curves

KW - Direct compression

KW - Plasticity

UR - http://www.scopus.com/inward/record.url?scp=0033913820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033913820&partnerID=8YFLogxK

U2 - 10.1081/DDC-100101331

DO - 10.1081/DDC-100101331

M3 - Article

C2 - 10914328

AN - SCOPUS:0033913820

VL - 26

SP - 1013

EP - 1018

JO - Drug Development and Industrial Pharmacy

JF - Drug Development and Industrial Pharmacy

SN - 0363-9045

IS - 9

ER -